iGlarLixi CGM Study in Chinese T2D Individuals After OADs
← catalyst calendarNCT06671587 · readout in 30 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
678estimated
Sites
1
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-10 | actual | When the study began enrolling |
| Primary completion | 2026-09-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-18 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type 2 Diabetes (T2D)
Interventions
- Drug: iGlarLixi (insulin glargine/lixisenatide) — also filed as SOLIQUA®
- Drug: Gla-100 (insulin glargine) — also filed as LANTUS®
Primary outcome
what the primary-completion date above is the date OFSuperiority of mean change in the percentage of TIR [3.9-10.0 mmol/L (70-180 mg/dL)]
measured from baseline to Week 20
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed